This metformin-PCK2-mediated signaling pathway could therefore be a novel mechanism for mitigating craniofacial malformation and osteoporosis, which thus opens up a new avenue for clinical treatment strategies for bone metabolic disorders. The gene discussed is PCK2; the disease is metabolic bone disorder.